C4 Therapeutics and Roche Forge $1B+ DAC Collaboration to Pioneer Degrader-Antibody Conjugates in Oncology
C4 Therapeutics, Inc. (NASDAQ: CCCC), a leader in targeted protein degradation (TPD), announced an expanded...
Lynk Pharmaceuticals’ JAK1 Inhibitor Zemprocitinib Enters NMPA Review for Atopic Dermatitis
Lynk Pharmaceuticals Co., Ltd., a clinical-stage Chinese biopharmaceutical company, announced that the National Medical Products...
Thermo Fisher Scientific Partners with Singapore’s PRECISE to Power Landmark Proteomics Study PRECISE-SG100K
Thermo Fisher Scientific Inc. (NYSE: TMO), the global life sciences leader, announced a strategic collaboration...
Shanghai Ark Bio Advances AK0406, a Next-Gen Long-Acting Influenza ADFC, into Phase I Trial in Australia
Shanghai Ark Biopharmaceutical Co., Ltd., a China-based clinical-stage biotech, announced that its investigational long-acting antiviral...
BeOne Medicines Secures NMPA Conditional Approval for Imdelltra (Tarlatamab) in Heavily Pretreated Small Cell Lung Cancer
BeOne Medicines Ltd. (NASDAQ: ONC, HKG: 6160, SHA: 688235), formerly BeiGene, announced that China’s National...
Oricell Therapeutics Secures $110M+ Pre-IPO Round to Advance First-in-Class CAR-T for Liver Cancer
Oricell Therapeutics Co., Ltd., a clinical-stage Chinese biotech developing next-generation CAR-T therapies, announced it has...
Duality Biologics’ HER2-Targeted ADC DB-1303 (BNT323) Enters NMPA Review for Metastatic Breast Cancer
Duality Biologics Co., Ltd. (HKG: 9606), a U.S.-China biotech specializing in antibody-drug conjugates (ADCs), announced...
IntuitiveFosun Partners with Sinopharm CDMC to Advance Surgical Robotics Adoption in China
IntuitiveFosun, the China-focused joint venture between Intuitive Surgical, Inc. (NASDAQ: ISRG) and Shanghai Fosun Pharmaceutical...
Haisco Pharma’s HSK42360 Selected for NMPA SPARK Program – First BRAF V600 Inhibitor for Pediatric Glioma in China
Haisco Pharmaceutical Group Co., Ltd (SHE: 002653) announced that its novel drug candidate HSK42360 has been...
Luye Pharma Doses First Patient in Phase II Study of LY03020 – World’s First Dual‑Target TAAR1/5‑HT2CR Agonist for Schizophrenia
Luye Pharma Group (HKG: 2186) announced first patient enrollment in a Phase II clinical study evaluating...
Sino Biopharm Wins FDA Approval for Pan‑KRAS Inhibitor TQB3205 – First‑in‑Human Trial in Advanced Malignancies
Sino Biopharmaceutical Ltd (HKG: 1177) announced that the US Food and Drug Administration (FDA) has granted...
GenFleet Therapeutics Secures First‑Ever NMPA Breakthrough Designation for KRAS G12D Inhibitor in Pancreatic Cancer
GenFleet Therapeutics (Shanghai) Inc. (HKG: 2595) announced that China’s National Medical Products Administration (NMPA) has granted...
Gan & Lee Licenses Bonfaglutide to JW Pharma for $81.1M – Expands GLP‑1 Footprint into South Korea
Gan & Lee Pharmaceuticals (SHA: 603087) announced a licensing agreement with JW Pharmaceutical, granting the South...
Grand Pharma Partners with HKU on Anti‑Infective Drug Discovery – Exclusive License Deal Targets Novel Antibacterial Therapies
Grand Pharmaceutical Group Co., Ltd. (HKG: 0512) announced a strategic partnership with The University of Hong...
Sino Biopharm’s Chia Tai Tianqing Secures GDMPA Approval for Naldemedine in Greater Bay Area – World’s First Oral OIC Therapy Enters China
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (CTTQ), a wholly‑owned subsidiary of Sino Biopharmaceutical Limited...
UniXell Biotechnology Secures NMPA IND Approval for UX-GIP001, World’s First iPSC-Derived Cell Therapy for Drug-Resistant Epilepsy
UniXell Biotechnology, a clinical-stage cell therapy innovator, announced that China’s National Medical Products Administration (NMPA)...
Shionogi Secures $119M BARDA Contract for Fetroja Antibiotic as Biothreat Countermeasure
Shionogi Co., Ltd. (TYO: 4507) announced that its U.S. subsidiary, Shionogi Inc., has been awarded...
Ascletis Pharma Advances Oral GLP-1R/Amylin Receptor Dual Agonist Combination ASC30/ASC39 for Obesity, Targeting Q3 FDA IND Submission
Ascletis Pharma Inc. (HKG: 1672) announced the selection of a fixed-dose combination (FDC) of ASC30...
Basecare Medical Secures NMPA Category III Approval for Gems Series IVF Culture Media, Expanding China’s Domestic Embryo Culture Solutions
Suzhou Basecare Medical Co., Ltd (HKG: 2170), a China-based in vitro fertilization (IVF) specialist, announced...
Wuhan Ammunition Life-tech Files Hong Kong IPO Prospectus, Pioneering Methylation-Based Early Cancer Detection with Liver and Urothelial Cancer Tests
Wuhan Ammunition Life-tech Co., Ltd. has filed its prospectus for an initial public offering (IPO)...